Please use this identifier to cite or link to this item:
Title: Insulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells
Author: Carpéné, Christian
Garcia-Vicente, Silvia
Serrano, Marta
Martí, Luc
Belles, Chloé
Royo Expósito, Miriam
Galitzky, Jean
Zorzano Olarte, Antonio
Testar, Xavier
Keywords: Teixit adipós
Resistència a la insulina
Adipose tissues
Insulin resistance
Issue Date: 15-Apr-2017
Publisher: Baishideng Publishing Group Inc
Abstract: This study investigates in murine and human adipocytes the antilipolytic properties of a conjugate of benzylamine and decavanadate (B6V10), already reported to lower hyperglycaemia in diabetic rodents. Data indicated that the conjugate dose-dependently inhibited submaximal activation of lipolysis in all the species studied. Such antilipolytic action deals with the in vivo FFA-lowering properties already described for B6V10 in diabetic rats. B6V10 also activated lipogenesis and glucose transport in fat cells. B6V10 should therefore be useful in preventing the lipotoxicity constituted by the unrestrained lipolytic activity of insulin-resistant adipocytes in obese individuals presenting type 2 diabetes, a state named diabesity.
Note: Reproducció del document publicat a:
It is part of: World Journal of Diabetes, 2017, vol. 8, num. 4, p. 143-153
Related resource:
ISSN: 1948-9358
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
672268.pdf1.32 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons